Immunogenicity and Safety Results of a Randomized, Three-Arm, Phase IV Clinical Trial of Concomitant Administration of Typhoid Vi Conjugate Vaccine with Measles and Rubella Vaccine in Healthy Infants
Authors:
- Songa Narayana RaoSRSonga Narayana Rao
- Deepali AmbikeDADeepali Ambike
- Mahantesh PatilMPMahantesh Patil
- Sanjay Vasant MankarSMSanjay Vasant Mankar
- Nishant VermaNVNishant Verma
- Neeta HanumanteNHNeeta Hanumante
- Lisa SarangiLSLisa Sarangi
- Monjori MitraMMMonjori Mitra
- Godatwar PreetiGPGodatwar Preeti
- Bhaskar Jedhe DeshmukhBDBhaskar Jedhe Deshmukh
- Girish NanotiGNGirish Nanoti
- Mohammad Moonis Akbar FaridiMFMohammad Moonis Akbar Faridi
Open Access
Abstract
Typhoid fever, measles, and rubella continue to contribute significantly to childhood morbidity and mortality in India. In line with WHO recommendations for co-administration of Typhoid Conjugate Vaccine (TCV) and measles–rubella (MR) vaccine at 9 months of age, this phase IV, randomized, open-label, multicenter clinical trial was conducted to assess their immunological compatibility and safety when administered concomitantly. A total of 900 healthy Indian infants aged 9–10 months were randomized into three groups: Group A received TCV and MR vaccine concomitantly; Group B received MR on Day 0 and TCV on Day 28; Group C received TCV on Day 0 and MR on Day 28. Subjects were followed for 6 months after concomitant/last vaccination. Seroconversion rates (SC) in Groups A/B/C at Day 28 were 90.2%/75.3%/89.5% for anti-Vi; 80.4%/75.2%/77.7% for anti-measles, and 87.7%/84.0%/85.2% for anti-rubella antibodies. By study end, SC for anti-Vi was 87.1%/71.6%/83.0%, while SC for anti-measles and anti-rubella reached ~90% and ≥98%, respectively, across all groups. Geometric mean titers increased significantly for all antigens, with no evidence of immunological interference. Safety assessments showed adverse events in 23.9%/32.0%/32.7% participants in Group A/B/C. Most adverse events were mild, and only one serious adverse event was reported. These findings support the co-administration of TCV and MR vaccine as a safe and effective strategy.Keywords
Funding Information
- Zydus Lifesciences Ltd.
This publication has 17 references indexed in Scilit:
- The global burden of enteric fever, 2017–2021: a systematic analysis from the global burden of disease study 2021eClinicalMedicine, 2024
- Burden of Typhoid and Paratyphoid Fever in IndiaNew England Journal of Medicine, 2023
- Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9–15 months old Nepalese infantsVaccine, 2022
- Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trialThe Lancet Global Health, 2022
- Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trialInternational Journal of Infectious Diseases, 2021
- Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina FasoInternational Journal of Infectious Diseases, 2021
- Complications and mortality of typhoid fever: A global systematic review and meta-analysisJournal of Infection, 2020
- The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017The Lancet Infectious Diseases, 2019
- Typhoid vaccines: WHO position paper, March 2018 – RecommendationsVaccine, 2019
- Interactions of conjugate vaccines and co-administered vaccinesHuman Vaccines & Immunotherapeutics, 2015